Spots Global Cancer Trial Database for Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Official Title: An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)
Study ID: NCT01596400
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
Detailed Description:
Keywords
Eligibility
Minimum Age: 13 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Locations
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Children's Hospital of Orange County, Orange, California, United States
Children's Hospital Colorado, Center for Cancer and Blood Disorders, Aurora, Colorado, United States
University of Florida, Gainesville, Florida, United States
Nemours Children's Clinic, Jacksonville, Florida, United States
University of South Florida, Tampa, Florida, United States
University of Mississippi Medical Center, Jackson, Mississippi, United States
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
UTSW/Childrens Medical Center, Dallas, Texas, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States
Madigan Army Medical Center, Tacoma, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
